Robert W. Duggan - 05 Jul 2023 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role: Director, 10%+ Owner
Signature: /s/ Kenneth B. Stratton, as Attorney-in-Fact
Issuer symbol: PLSE
Transactions as of: 05 Jul 2023
Net transactions value: +$289,112
Form type: 4
Filing time: 07 Jul 2023, 18:26:49 UTC
Previous filing: 16 Jun 2023
Next filing: 27 Jul 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PLSE	Common Stock	Options Exercise	$139,100	+65,000	+0.18%	$2.14	36,162,824	05 Jul 2023	Direct
transaction	PLSE	Common Stock	Options Exercise	$140,099	+65,467	+0.18%	$2.14	36,228,291	07 Jul 2023	Direct
transaction	PLSE	Common Stock	Options Exercise	$9,913	+1,666	+0%	$5.95	36,229,957	07 Jul 2023	Direct
holding	PLSE	Common Stock						492,069	05 Jul 2023	See footnote	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PLSE	Stock Option (right to buy)	Options Exercise	$0	-65,000	-50%	$0.000000	65,467	05 Jul 2023	Common Stock	65,000	$2.14	Direct	F2
transaction	PLSE	Stock Option (right to buy)	Options Exercise	$0	-65,467	-100%	$0.000000^*	0	07 Jul 2023	Common Stock	65,467	$2.14	Direct	F2
transaction	PLSE	Stock Option (right to buy)	Options Exercise	$0	-1,666	-8.3%	$0.000000	18,334	07 Jul 2023	Common Stock	1,666	$5.95	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder.
F2	All of the shares subject to the option are fully vested and exercisable as of the date hereof.
F3	Pursuant to the Company's Amended and Restated Outside Director Compensation Policy, this option vests on a monthly basis following the Company's last Annual Stockholder Meeting.